Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352526 | 0.96 | MAPT (0.51) | MAPTL3MBTL1CASP3ALDH1A1LMNA | |
| SCHEMBL18355267 | 0.88 | MAPT (0.50) | MAPTL3MBTL1CASP3ALDH1A1 | |
| SCHEMBL18353030 | 0.84 | MAPT (0.53) | MAPTL3MBTL1CASP3ALDH1A1 | |
| SCHEMBL18355463 | 0.83 | LMNA (0.42) | MAPTCASP3ALDH1A1LMNACYP2D6 | |
| SCHEMBL18354908 | 0.79 | HCAR2 (0.38) | — | |
| SCHEMBL18364216 | 0.79 | MAPT (0.61) | MAPTL3MBTL1ALDH1A1LMNACYP2D6 | |
| SCHEMBL18364242 | 0.79 | MAPT (0.61) | MAPTL3MBTL1ALDH1A1LMNACYP2D6 | |
| SCHEMBL18364210 | 0.79 | MAPT (0.61) | MAPTL3MBTL1ALDH1A1LMNACYP2D6 | |
| SCHEMBL18352649 | 0.79 | LMNA (0.44) | MAPTCASP3ALDH1A1LMNACYP2D6 | |
| SCHEMBL18364308 | 0.79 | MAPT (0.57) | MAPTL3MBTL1ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | MAPT 8/4885L3MBTL1 4164/4885CASP3 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.